Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
about
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivoDevelopment and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 proteaseCoagulation factor XII protease domain crystal structure.Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors3D deep convolutional neural networks for amino acid environment similarity analysisA urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.Imaging active urokinase plasminogen activator in prostate cancer.Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.Application of Molecular Modeling to Development of New Factor Xa InhibitorsInhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis.A pilot study of urokinase-type plasminogen activator (uPA) overexpression in the brush cytology of patients with malignant pancreatic or biliary strictures.The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells.Anti-metastatic effect of deoxyelephantopin from Elephantopus scaber in A549 lung cancer cells in vitro.Human airway trypsin-like protease, a serine protease involved in respiratory diseases.Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.Tripeptides with non-code amino acids as potential serine proteases inhibitors.Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.Synthesis and Biological Activity of N-Sulfonyltripeptides with C-Terminal Arginine as Potential Serine Proteases Inhibitors.Comparative binding energy analysis for binding affinity and target selectivity prediction.Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.Optimization of Substrate-Analogue Furin Inhibitors.Thrombin-Inhibiting Anticoagulant Liposomes: Development and Characterization.Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells.Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
P2860
Q24539093-F1BE2EBC-4D02-4931-9EB1-854172EEC1ADQ27683750-CA9E14FD-BFC6-47D5-BD71-8F54AE4386FAQ30370920-9CDCDE37-2ED5-406A-B6BB-2BC3B057F044Q30386796-50837D89-70C9-4976-838C-2C920AB74D27Q30403066-5E75958D-EB44-489F-8CE1-94C42D035007Q33222784-56A6386E-8C33-47A1-A1B3-662AD4F87DB5Q33664568-E368E0A4-2616-4D00-B14E-B76F55FBFDCBQ34073304-BEC95EEB-E5B5-465F-8DE1-8AD207EF2C0BQ35251858-39548CCA-3E28-4303-9F4C-3DCE4C586543Q35672193-1E8448C9-0941-414F-A000-4966277B2D97Q35699282-30BC1257-95F9-4789-BC1D-3BBDEE1F290DQ35898448-C8E99AD4-A928-4F9C-90B4-0D27418CE9A6Q36052463-11FC7AB7-DC6E-4377-9083-01C685CF4FBCQ36119724-77A98BE0-3130-4712-840D-16BA335084EEQ36302249-0AE405A6-FB9C-4C9C-A7A4-9D98791D5290Q37071920-314059FB-8BA4-4591-AE2C-E918514BB1D4Q37452991-71DE5A71-DB17-41B0-8B05-1D7239BBC8BAQ37728861-4DFFCB0C-367D-4203-8342-50717BAFE03CQ38909057-5893896B-61E0-4CA2-B2CD-77097519023EQ39149977-1337FCD2-D669-45B3-97AC-EE30594CFA62Q39175999-C5F94192-BD15-485D-BA14-1A1E6840FAB1Q39402728-696060D6-79EF-4214-89B8-5F5EE9718FA0Q39925886-9EF3D77D-B0AB-4365-A65E-9C9C4DE1F4A2Q40443951-01AD5E45-41FA-40EF-8334-C04605E29994Q42062362-D3495208-3EBA-487E-8059-E9E82339F4EFQ43273730-B0190A74-A4E5-42F4-ACB2-ADCADC214B81Q47098588-D29D17F9-1837-49DD-AEF6-F6E4769E20EFQ47420797-193895E9-E936-4B4D-8560-D2ECE2528FECQ48089546-67870891-9899-457B-99B2-9B6C4D138800Q50915592-927DBF5A-CB6D-46FC-B767-2028B504953BQ53099256-2BB39E2E-FADC-4CD4-8FB6-4652799B2751Q53732349-59768CAD-C1A0-417E-91D4-6241CC74AD37
P2860
Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Design of novel and selective ...... use as antimetastatic agents.
@en
Design of novel and selective ...... use as antimetastatic agents.
@nl
type
label
Design of novel and selective ...... use as antimetastatic agents.
@en
Design of novel and selective ...... use as antimetastatic agents.
@nl
prefLabel
Design of novel and selective ...... use as antimetastatic agents.
@en
Design of novel and selective ...... use as antimetastatic agents.
@nl
P2093
P2860
P356
P1476
Design of novel and selective ...... use as antimetastatic agents.
@en
P2093
Achim Krüger
Andrea Schweinitz
Andreas Geissler
Anne Stürzebecher
Ewa Zeslawska
Helmut Giersiefen
Ingo J Banke
Jörg Stürzebecher
Matthias J E Arlt
Oliver Schuster
P2860
P304
33613-33622
P356
10.1074/JBC.M314151200
P407
P577
2004-05-18T00:00:00Z